Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles
Access StatusFull text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.
Eaton, John K.
Ryan, Matthew J.
Cai, Luke L.
Hillig, Roman C.
Lazarski, Kiel E.
Eheim, Ashley L.
Viswanathan, Vasanthi S
Schreiber, Stuart L
MetadataShow full item record
CitationEaton, John K., Laura Furst, Richard Ruberto, Dieter Moosmayer, André Hilpmann, Matthew J. Ryan, Katja Zimmermann et al. "Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles." Nat Chem Biol 16, no. 5 (2020): 497-506. DOI: 10.1038/s41589-020-0501-5
AbstractWe recently described glutathione peroxidase 4 (GPX4) as a promising target for killing therapy-resistant cancer cells via ferroptosis. The onset of therapy resistance by multiple types of treatment results in a stable cell state marked by high levels of polyunsaturated lipids and an acquired dependency on GPX4. Unfortunately, all existing inhibitors of GPX4 act covalently via a reactive alkyl chloride moiety that confers poor selectivity and pharmacokinetic properties. Here, we report our discovery that masked nitrile-oxide electrophiles, which have not been explored previously as covalent cellular probes, undergo remarkable chemical transformations in cells and provide an effective strategy for selective targeting of GPX4. The new GPX4-inhibiting compounds we describe exhibit unexpected proteome-wide selectivity and, in some instances, vastly improved physiochemical and pharmacokinetic properties compared to existing chloroacetamide-based GPX4 inhibitors. These features make them superior tool compounds for biological interrogation of ferroptosis and constitute starting points for development of improved inhibitors of GPX4.
Citable link to this pagehttps://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37374459
- FAS Scholarly Articles